Insight Molecular Diagnostics Current Ratio 2014-2025 | IMDX
Insight Molecular Diagnostics current ratio from 2014 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Insight Molecular Diagnostics Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-03-31 | $0.04B | $0.01B | 3.75 |
| 2024-12-31 | $0.01B | $0.01B | 1.62 |
| 2024-09-30 | $0.01B | $0.01B | 0.53 |
| 2024-06-30 | $0.01B | $0.01B | 1.39 |
| 2024-03-31 | $0.01B | $0.01B | 0.79 |
| 2023-12-31 | $0.01B | $0.01B | 1.49 |
| 2023-09-30 | $0.02B | $0.01B | 2.11 |
| 2023-06-30 | $0.02B | $0.01B | 2.74 |
| 2023-03-31 | $0.02B | $0.01B | 1.66 |
| 2022-12-31 | $0.03B | $0.01B | 2.11 |
| 2022-09-30 | $0.04B | $0.01B | 2.83 |
| 2022-06-30 | $0.05B | $0.01B | 3.49 |
| 2022-03-31 | $0.03B | $0.01B | 1.76 |
| 2021-12-31 | $0.04B | $0.01B | 2.77 |
| 2021-09-30 | $0.05B | $0.01B | 3.56 |
| 2021-06-30 | $0.05B | $0.02B | 2.53 |
| 2021-03-31 | $0.06B | $0.01B | 6.49 |
| 2020-12-31 | $0.01B | $0.01B | 1.03 |
| 2020-09-30 | $0.01B | $0.01B | 1.35 |
| 2020-06-30 | $0.02B | $0.01B | 2.70 |
| 2020-03-31 | $0.02B | $0.01B | 2.62 |
| 2019-12-31 | $0.02B | $0.00B | 5.17 |
| 2019-09-30 | $0.02B | $0.00B | 6.66 |
| 2019-06-30 | $0.04B | $0.00B | 9.13 |
| 2019-03-31 | $0.04B | $0.00B | 12.82 |
| 2018-12-31 | $0.01B | $0.01B | 1.55 |
| 2018-09-30 | $0.01B | $0.01B | 2.58 |
| 2018-06-30 | $0.01B | $0.00B | 2.54 |
| 2018-03-31 | $0.01B | $0.01B | 2.57 |
| 2017-12-31 | $0.01B | $0.00B | 1.92 |
| 2017-09-30 | $0.01B | $0.01B | 2.69 |
| 2017-06-30 | $0.01B | $0.01B | 2.19 |
| 2017-03-31 | $0.01B | $0.01B | 2.96 |
| 2016-12-31 | $0.01B | $0.00B | 2.97 |
| 2016-09-30 | $0.02B | $0.00B | 3.85 |
| 2016-06-30 | $0.01B | $0.00B | 2.12 |
| 2016-03-31 | $0.01B | $0.00B | 2.87 |
| 2015-12-31 | $0.01B | $0.00B | 4.72 |
| 2015-09-30 | $0.00B | 0.00 | |
| 2015-06-30 | $0.00B | 0.00 | |
| 2015-03-31 | $0.00B | 0.00 | |
| 2014-12-31 | $0.00B | $0.01B | 0.58 |
| 2013-12-31 | $0.01B | $0.01B | 1.04 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.082B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.084B | 57.36 |
| Doximity (DOCS) | United States | $11.307B | 52.35 |
| Hims & Hers Health (HIMS) | United States | $10.719B | 111.37 |
| Tempus AI (TEM) | United States | $9.847B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.340B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.842B | 60.03 |
| Hinge Health (HNGE) | United States | $3.717B | 0.00 |
| Privia Health (PRVA) | United States | $2.496B | 170.58 |
| Enovis (ENOV) | United States | $1.944B | 10.84 |
| Phreesia (PHR) | United States | $1.590B | 0.00 |
| 10x Genomics (TXG) | United States | $1.576B | 0.00 |
| Schrodinger (SDGR) | United States | $1.542B | 0.00 |
| Azenta (AZTA) | United States | $1.532B | 71.21 |
| Clover Health Investments (CLOV) | United States | $1.486B | 0.00 |
| Omnicell (OMCL) | United States | $1.344B | 23.71 |
| Evolent Health (EVH) | United States | $1.313B | 111.80 |
| Claritev (CTEV) | United States | $0.761B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.587B | 0.00 |
| Veradigm (MDRX) | United States | $0.547B | 0.00 |
| Standard BioTools (LAB) | United States | $0.501B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.448B | 0.00 |
| Talkspace (TALK) | United States | $0.442B | 132.00 |
| Outset Medical (OM) | United States | $0.344B | 0.00 |
| TruBridge (TBRG) | United States | $0.331B | 735.33 |
| Health Catalyst (HCAT) | United States | $0.271B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.258B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.233B | 0.00 |
| CapsoVision (CV) | United States | $0.212B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.161B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.150B | 0.00 |
| American Well (AMWL) | United States | $0.131B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.123B | 0.00 |
| Pulmonx (LUNG) | United States | $0.117B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.103B | 0.00 |
| CareCloud (CCLD) | United States | $0.101B | 3.84 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.068B | 0.00 |
| 111 (YI) | China | $0.065B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.045B | 0.00 |
| HeartBeam (BEAT) | United States | $0.042B | 0.00 |
| Zhongchao (ZCMD) | China | $0.029B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.009B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.005B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |